240 results about "Clarithromycin" patented technology

The invention relates to clear, stable topical compositions of clarithromycin for the treatment of acne and processes for their preparation. The transparent topical compositions include clarithromycin, a zinc salt, a pharmaceutically acceptable vehicle and may include gelling agents.

There is disclosed the formulation of a poorly soluble macrolide antibiotic, such as clarithromycin together with beta-cyclodextrin, and optionally a dicarboxylic acid wherein the particles of the formulation are prepared using microfluidization techniques in a particle size in the range of from 5 to 15 microns.

The invention belongs to the fields of genetic engineering and medical inspection, and relates to a biochip for detecting drug resistant genes of drug resistant genes and a preparation method and an application thereof. The biochip is prepared by the following steps: carrying out aldehyde processing for a chip base; connecting a 5' end of a probe with a molecule arm of poly (dT)10; then carrying out amino modification for the 5' end of the probe; aiming at the mutants at the following positions of helicobacter pylori 23S rRNA genes by the probe: A2115G, A2142G, A2142C, A2143G, A2143C, T2182C and G2224A; and fixing the probe on the chip base. The biochip has high sensitivity, good specificity and low detection cost, can distinguish the difference of monobasic bases, and is suitable for being popularized and used in establishment units.

The invention discloses a method for improving erythrocin yield through a negative control gene SACE_3446 on an inactivation saccharopolyspora erythraea chromosome. Saccharopolyspora erythraea is used for producing erythrocin. The erythrocin and derived drugs of the erythrocin such as clarithromycin, azithromycin and telithromycin are used widely in clinic. Erythrocin high-producing strain screening is very important in industrial production. The erythromycin biosynthesis negative control gene SACE_3446 is screened from a saccharopolyspora erythraea TetR family. Compared with erythrocin yield of an original strain, deletion mutants of the saccharopolyspora erythraea SACE_3446 is improved remarkably, the erythrocin is returned to low yield after gene complementation of the SACE_3446, and therefore the SACE_3446 gene is a erythromycin biosynthesis negative control gene. The inactivation saccharopolyspora erythraea SACE_3446 gene can improve the erythrocin yield through a genetic engineering way. Due to the fact that erythromycin biosynthesis gene control is a network system, upstream and downstream control factors acted by SACE_3446 control factors can be found by using the SACE_3446 as an object. The erythrocin yield can also be improved by changing upstream or downstream control factor genes of the saccharopolyspora erythraea SACE_3446 control factors.

The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

The invention mainly discloses a silanization reaction catalyst. Etherate is obtained by erythromycin oxime through etherification, (2', 4'')-O-bis(trimethylsilyl)erythromycin A-9-O-(1-ethoxy-1-methylethyl) oxime of intermediate for synthesizing clarithromycin is prepared by the silanization reaction, the catalyst is added into the silanization reaction and is hydrobromide with a general formula being RHBr, wherein R is organic alkali, or the catalyst is strong acid and weak base salt with a general formula being XBr, wherein X is weak base cations. The consumption of the catalyst is 0.01-0.4 of the erythromycin oxime according to the mol, the temperature of the silanization catalysis reaction is 0-40 DEG C and the time of the silanization catalysis reaction is 1-10h. The invention enables the process for preparing the (2', 4'')-O-bis(trimethylsilyl)erythromycin A-9-O-(1-ethoxy-1-methylethyl) oxime to be stable, the yield to be high, the cost to be low and the three wastes to be less.

The invention provides a kit used for detecting helicobacter pylori drug resistance gene mutation via multiple fluorescent PCR. The kit can be used for detecting helicobacter pylori drug resistance gene mutation of gastric mucosa tissue samples, and determining whether drug resistance is generated. The kit comprises following drugs and drug resistance gene mutation sites: clarithromycin (2142A>G, 2143A>G, 2182C>T), tetracycline (926-928AGA>TTC), quinolones (Asn87-Lys, Ala88-Val, Asp91-Gly), and amoxicillin (S414R, Y484C, and P600T). The kit can be used for obtaining accurate results in a short time, and is suitable for guidance of personalized medicine of helicobacter pylori in clinical treatment.

The invention mainly discloses methylation reaction in a clarithromycin synthesis process and a recycling method of a methylation reagent. In the methylation reaction, methyl benzenesulfonate is used as the methylation reagent, potassium hydroxide is used as a catalyst, and methyl tertbutyl ether and dimethyl sulfoxide are used as solvents. After the methylation reaction, water is added for stratification, the dimethylsulfoxide (DMSO) layer is recycled and dried to obtain P-methyl benzene potassium sulfonate, dimethylsulfoxide is added for reaction to obtain P-methyl benzene sulfonyl chloride, and P-methyl benzene methyl sulfonate is regenerated via reaction with methanol. The generation of bismethyl impurities can be avoided effectively. Meanwhile, P-methyl benzene methyl sulfonate is regenerated via reaction of the dimethylsulfoxide and the methanol, and thus the recycling of the methylation reagent is realized.

The present invention provides a clarithromycin dispersible tablet preparation method, which comprises: carrying out ultrafine crushing on clarithromycin and part of lactose into micro-powder with the diameter of less than 10 [mu]m to obtain mixed powder A; taking the remaining filler and part of a disintegrant, and mixing to form mixed powder B; mixing an adhesive and purified water to prepare an aqueous solution with the mass fraction of 1-10%; mixing the mixed powder B with the mixed powder A in an equal increase manner, placing into a three-dimensional mixer to mix for 30-40 min, adding to the adhesive aqueous solution to prepare a soft material, and screening with a 16-24 mesh sieve; drying at a temperature of 50-70 DEG C, and screening the whole particle with a 16-24 mesh sieve; externally adding the remaining disintegrant, a lubricant and a sweetener to the particles to obtain a material C; and tableting the material C to obtain the clarithromycin dispersible tablets. According to the invention, the clarithromycin and part of the lactose are subjected to ultrafine crushing, such that the particle size is small, the specific surface area is increased, the adsorption property and the solubility are correspondingly increased, the bitterness of the product can be reduced, and the patient compliance can be improved; and with the process, the clarithromycin dispersible tablet with characteristics of stable quality, rapid drug dissolution and no bad odor can be prepared.

The invention discloses novel application of a pyrazolo[1, 5-a]pyridine compound and a composition for treatment of Mycobacterium abscessus infection. The pyrazolo[1, 5-a]pyridine compound can be used for preparation of an anti-Mycobacterium abscessus synergist of clofazimine, combined use of the two can reach a synergistic effect, and a low concentration pyrazolo[1, 5-a]pyridine compound can reinforce the anti-Mycobacterium abscessus effect of clofazimine. The active components of the composition for treatment of Mycobacterium abscessus infection provided by the invention contain clofazimine and/or macrolide antibiotic, and the pyrazolo[1, 5-a]pyridine compound serving as a synergist. The composition has the characteristics of rapid effect, no relapse after treatment, and efficacy significantly superior to the combined use of clarithromycin and amikacin, and overcomes the shortcomings of easy generation of induced drug-resistance and poor long-term treatment effect in existing macrolide antibiotic clinical treatment.

The invention relates to Clarithromycin derivatives, the preparing process and medicinal use, the Clarithromycin derivatives have general formulas of (I), (II), these compounds and the medicinal compositions of them can be used for treating infectious diseases caused by sensitive organisms and other pathogenic agents.

The present invention relates to one kind of Clarithromycin injection, and is especially one bacteria-free powder and solution of water soluble Clarithromycin salt for injection. The injection of the present invention has water soluble Clarithromycin salt, preferably hydrochloride and tartrate of Clarithromycin, as its active component. The present invention also provides the preparation processof bacteria-free powder and solution of water soluble Clarithromycin salt for injection.

The invention describes a composition suitable for oral administration comprising and antibiotic macrolide and a polycarbophil. The antibiotic macrolide is preferably clarithromycin. The polycarbophil is reported to have surprising taste-masking properties in combination with the antibiotic and acts by inhibiting the undesirable release of the antibiotic component in the mouth or stomach. Several methods of preparing granules of the antibiotic macrolide said polycarbophil are also described.

The invention relates to a method for preparing clarithromycin debitterized granules, which comprises the following steps: (1) preparing solution of coating: preparing solutions A, B and C respectively, then, mixing the solutions evenly, and adding pure water for later use; and (2) coating: coating 2,000g of 60 to 120-mesh powdery clarithromycin with the coating solution with the specific coating parameters being fluidized coating/drying; preheating the coating system to the temperature of 38 DEG C, and spraying the coating system with the inlet temperature being 36 to 60 DEG C, the atomization pressure being 0.08 to 0.45 MPa and the flow rate of the spray solution being 2 to 120 ml/min; and proceeding with drying for 20min and collecting pellets with the pellet diameter being 80 to 800 Mum. The invention has the advantages that the materials are easily obtainable, the cost is low and the preparation method is simple and environment-friendly, therefore, the method is favorable for industrialized production; moreover, the prepared granules solve the problem that the bitter taste is insufferable during the oral administration and make the forms of the oral preparation richer and the range of those who take the granules wider, and the granules are particularly suitable for children to take.